This randomized, retrospective study evaluated the effect of thalidomide combined with bortezomibdexamethasone (TBD) or vincristinedoxorubicin-dexamethasone (T-VAD) on 46 patients with multiple myeloma. Newly diagnosed patients were randomly allocated to receive TBD (n = 24) or T-VAD (n = 22). The high-quality response rate (complete response plus very good partial response) was 62.5% in the TBD group and 45.4% for T-VAD. The complete response rate was 29.2% for TBD and 13.6% for T-VAD. Overall survival at 2 and 3 years, respectively, was 91.7% and 62.5% for TBD versus 86.4% and 54.5% for T-VAD. Most of the toxic effects of treatment were well tolerated. Both regimens were effective in the treatment of newly diagnosed multiple myeloma patients. Further studies are required to determine the role of thalidomide in these two regimens.
Introduction
Multiple myeloma (MM), a malignancy of Bcell origin, is the second most common haematological cancer after non-Hodgkin's lymphoma 1 and has a high incidence in the elderly. 2 Malignant plasma cells multiply uncontrollably, infiltrating the bone marrow and increasing monoclonal protein levels in the blood and/or urine. 3 Disease symptoms include skeletal destruction, bone marrow failure, suppression of normal immunoglobulin (Ig) production and renal insufficiency. 3 Vincristine-doxorubicindexamethasone (VAD) is considered the standard treatment for MM because of rapid response and lack of damage to stem cells. 4 Several factors obviate the advantages of this regimen, including the inconvenience and high cost of the required 4-day continuous infusion, 5 low complete response (CR) rate (generally < 10%), 6 risk of cathether-related complications (e.g. infections and a These authors contributed equally to this study.
RA Chen, Y Tu, Y Cao et al. TBD versus T-VAD in multiple myeloma thrombosis) 7 and toxicity. 8, 9 An alternative to VAD, melphalan-prednisone, has been shown over the past 30 years to have a 50% response rate and 2 -3 years' median overall survival (OS) rate, resulting in it being the treatment of choice for patients ineligible for high-dose therapy. 10, 11 High-dose therapy together with autologous stem cell transplantation is considered the standard treatment for newly diagnosed MM patients < 65 years old, because of its high response rate and relatively low morbidity and mortality in comparison with standard-dose therapy. 12 This regimen is not suitable for all patients, however, and many who receive this treatment will eventually relapse, 13 necessitating alternative therapeutic strategies.
In the front-line treatment of patients not eligible for transplantation, regimens incorporating novel agents, such as bortezomib and thalidomide, have been found to be superior to melphalanprednisone. 14, 15 The ubiquitin-proteasome pathway is important in the development of MM 16 and preclinical studies have shown proteasome inhibitors to be active against this disease. 17 Bortezomib, a cell-permeable dipeptidyl boronic acid, is a specific and selective inhibitor of the 26S proteasome. 18 It is known to induce apoptosis and growth arrest and reverse chemoresistance in multiple myeloma cells, 17, 19 and is currently being evaluated in a number of clinical trials as part of front-line MM therapy. The European Agency for the Evaluation of Medicinal Products has approved bortezomib as a monotherapy for use in MM patients who have received at least one prior treatment regimen and have undergone, or are unsuitable for, bone marrow transplantation.
Thalidomide was withdrawn from use in the early 1960s because of severe teratogenic effects; however, the recognition of the importance of angiogenesis in myeloma led to its re-evaluation as an antimyeloma agent. 20 Thalidomide possesses remarkable antitumour efficacy and has been investigated as a first-line therapy for symptomatic MM, both alone and in combination with dexamethasone. 21, 22 VAD plus thalidomide has been shown to give an objective response rate of 88% and a CR rate of up to 30% in the treatment of MM. 5 The expanded treatment options afforded by the use of novel agents such as thalidomide and bortezomib have improved the outcome of MM. The present study was a retrospective analysis of patients treated either with thalidomide combined with bortezomibdexamethasone or with VAD. 23, 24 and quantifiable levels of monoclonal protein (M-protein). Measurable disease was defined as at least 1 g/dl of IgG, 0.5 g/dl of IgA or 0.2 g/dl of IgM on serum electrophoresis. Patients with light chain disease or non-secretory MM (who did not show any M-protein at diagnosis) were included in the study if they had serum free light chain (SFLC) concentrations of 3.3 -19.4 mg/l for κ or 5.7 -26.3 mg/l for λ, assessed via the FreeLite™ SFLC assay (The Binding Site, San Diego, CA, USA) as described elsewhere. 25 Other inclusion criteria were: Karnofsky performance status ≥ 50%; 26 serum aspartate aminotransferase RA Chen, Y Tu, Y Cao et al.
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(AST) and alanine aminotransferase (ALT) ≤ 3 times the upper limit of the normal range (AST, men 40 U/l; women 28 U/l; ALT, 49 U/l); total serum bilirubin ≤ 2 times the upper limit of the normal range (20.5 µmol/l); and measured or calculated creatinine clearance > 10 ml/min. Exclusion criteria included: renal insufficiency (creatinine level ≥ 25 mg/l); uncontrolled or severe cardiovascular disease; psychiatric disease; any grade 2 peripheral neuropathy, other malignancy within the past 5 years; and hypersensitivity to bortezomib, boron or mannitol.
The study was approved by the Research Ethics Committee of Tangdu Hospital, Fourth Military Medical University, Xi'an, China. Written informed consent was obtained from all participants. Data were rendered anonymous as required by ethical and legal standards.
TREATMENT REGIMEN
Patients received one of two treatment regimens: thalidomide-bortezomib-dexamethasone (TBD) or thalidomidevincristine-doxorubicin-dexamethasone (T-VAD), with randomization occurring according to date of hospitalization. All patients received thalidomide at an initial oral dose of 100 mg/day, increasing in 50 mg/day increments each week to a maximum tolerated dose of 200 mg/day. Aspirin 100 mg/day was administered orally as anticoagulant prophylaxis during thalidomide treatment.
Patients on the TBD regimen received 1.3 mg/m 2 bortezomib as an i.v. bolus injection on days 1, 4, 8 and 11, and 20 mg dexamethasone orally on days 1 -4 and 8 -11 for a minimum of four and maximum of six cycles. Treatment was suspended in the event of drug-related toxicity (≥ grade 3 nonhaematological or grade 4 haematological toxicity). The TBD treatment was resumed with 1.0 mg/m 2 bortezomib when nonhaematological toxicity had reduced to ≤ grade 2 or, in the case of haematological toxicity, an absolute neutrophil count of ≥ 0.5 × 10 9 /l and platelet count of ≥ 30 × 10 9 /l.
Patients on the T-VAD regimen received 0.4 mg/day vincristine and 9 mg/m 2 per day doxorubicin continuous infusion on days 1 -4, 40 mg dexamethasone orally on days 1 -4, 9 -12 and 17 -20, monthly for a minimum of four cycles and a maxiumum of six cycles. Granulocyte colony-stimulating factor could be given to any patient in order to boost white blood cell counts < 5000 /ml whenever it was deemed necessary by the treating physician.
EVALUATION OF TREATMENT RESPONSE
Response to treatment was evaluated according to published international uniform response criteria, 25 and was defined as follows: complete response (CR) -negative serum and/or urine immunofixation and < 5% bone marrow plasma cells; very good partial response (VGPR) -≥ 90% reduction in immuno fixation-detected serum M-protein and urinary M-protein excretion < 100 mg/24 h; partial response (PR) -≥ 50% reduction in serum M-protein, reduction in 24-h urinary M-protein by ≥ 90% or to < 200 mg/24 h, and ≥ 50% reduction in bone marrow plasma cells; progressive disease (PD) -≥ 25% increase in serum and/or urinary M-protein or bone marrow plasma cells (absolute amount ≥ 10%); minor response (MR) -≥ 25% reduction in serum Mprotein and ≥ 50% reduction in 24-h Mprotein excretion. In non-secretory MM patients, regression of bone marrow plasma cell infiltration by > 95%, ≥ 50% and ≥ 25% defined CR, PR and MR, respectively. Disease was defined as stable if the criteria for CR, VGPR, PR or PD were not met. Toxic events RA Chen, Y Tu, Y Cao et al.
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were graded according to the National Cancer Institute Common Terminology Criteria (version 3). 27 Bone marrow plasma cells were purified using anti-CD138-coated magnetic beads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), according to the manufacturer's instructions, prior to conducting fluorescence in situ hybridization analysis for cytogenetic abnormalities relating to the diseases of interest.
The OS rate was calculated from the date of enrolment until the date of death or the date the patient was last known to be alive. Progression-free survival (PFS) was calculated from the date of enrolment until the date of progression, relapse, death or the date the patient was last known to be in remission.
STATISTICAL ANALYSES
Statistical analyses were performed using the SPSS ® statistical package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Differences in response between treatment groups were compared using the χ 2 -test. Differences in continuous measurements were compared with the Student's t-test. Time-to-event analyses were performed with the Kaplan-Meier method. A P-value < 0.05 was considered statistically significant.
Results
PATIENT CHARACTERISTICS
The study included 46 newly diagnosed MM patients (25 males, 21 females) with a median age of 57 years (range 44 -72 years; five patients [10.9%] ≥ 65 years). There were 24 patients in the TBD group and 22 in the T-VAD group. The patients' clinical characteristics are given in Table 1 ; there were no significant between-group differences.
RESPONSE TO THERAPY
The responses to TBD and T-VAD are given in Table 2 . There was no significant betweengroup difference in the rate of objective response, defined as PR or better (79.1% for TBD, 72.7% for T-VAD). The rate of highquality response (VGPR + CR) was higher in the TBD group than the T-VAD group (62.5% versus 45.4%, respectively) although this difference was not statistically significant. Patients in the TBD group had a higher CR rate (29.2%) than T-VAD patients (13.6%) although this difference was also not statistically significant.
TREATMENT TOXICITY
Treatment-related toxic effects are listed in Table 3 . The most common were peripheral neuropathy and infection. In spite of anticoagulant prophylaxis, deep venous thrombosis (DVT) occurred in 16.7% of the TBD group and 27.3% of the T-VAD group. Other commonly reported toxic effects ≥ grade 2/grade 3 27 were thrombocytopaenia, granulocytopaenia, constipation, fatigue, diarrhoea and vomiting. The main toxicities of T-VAD were haematological, particularly neutropaenia. TBD-related thrombocytopaenia was cyclical, occurring during the administration of bortezomib and recovering to baseline during the remainder of the treatment cycle. None of the patients discontinued treatment because of toxic effects.
SURVIVAL
Progression-free survival is shown in Fig. 1 . The median time to disease progression was 38 months (95% confidence interval [CI] 32 -44 months) in the TBD group and 30 months in the T-VAD group (95% CI 22 -37 months); a non-significant difference. There was also no significant between-group difference in OS (2-and 3-year OS rate was 91.7% and 62.5% for TBD versus 86.4% and 54.5% for T-VAD, respectively; Fig. 2 ).
Patient response TBD (n = 24) T-VAD (n = 22)
Complete response (CR) 7 Data presented as number (%) of patients. There were no statistically significant between-group differences.
TABLE 2: Response of the multiple myeloma patients to either thalidomide-bortezomib-dexamethasone (TBD), or thalidomide-vincristine-doxorubicin-dexamethasone (T-VAD) treatment
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Discussion
Singhal et al. 28 was the first to explore thalidomide for the treatment of advanced and refractory MM, reporting response rates of around 30%. Thalidomide is thought to affect the tumour and bone marrow microenvironment via disruption of myeloma/bone marrow stromal cell 
TABLE 1: Clinical characteristics of the multiple myeloma patients who received either thalidomidebortezomib-dexamethasone (TBD), or thalidomide-vincristine-doxorubicindexamethasone (T-VAD)
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interactions, inhibition of cytokine secretion, antiangiogenic activity and immunomodulatory effects. 29, 30 For combined thalidomide-dexamethasone therapy, a higher overall response rate of 66% has been reported, 31 which is slightly higher than the 55% response rate reported for VAD 5 . Generally, when thalidomide is used in combination with alkylating agents or corticosteroids, response rates of about 50% and 70%, respectively, are seen. 32 Treatment of previously untreated MM patients with a combination of thalidomide and VAD resulted in a CR rate of 10% and PR rate of 64%. 33 The proteasome inhibitor, bortezomib, rapidly but reversibly binds to a single threonine in the active site of the 20S proteolytic core and is indicated as a novel agent for the treatment of MM. 34, 35 Bortezomib affects numerous regulatory proteins necessary for the proliferation of malignant cells, leading to apoptosis. 17 At the same time, it inhibits the binding of myeloma cells to the stroma, affecting the microenvironment, 34 as well as downregulating interleukin-6-triggered cascades. 36 In particular, these effects of bortezomib on MM mean that it does not correlate with most standard prognostic factors. 37, 38 Clinical trials of bortezomib have established a dosage regimen (1.3 mg/m 2 on days 1, 4, 8 and 11 in 3-week cycles) and proven its efficacy alone and in combination with dexamethasone. 39 Compared with high-dose dexamethasone, bortezomib produced a response in more patients (18% versus 38%), extended the median time to progression (3.49 versus 6.22 months) and increased the 1-year survival rate (66% versus 80%). 40 Clinical studies and laboratory research have verified the Data presented as number (%) of patient. There were no statistically significant between-group differences. a Toxic events were graded according to the National Cancer Institute Common Terminology Criteria (version 3). 27 
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chemosensitizing and radiosensitizing effects of this agent in patients with MM. 41, 42 All patients in the current study received both thalidomide and dexamethasone, but the dexamethasone treatment regimen differed between the two groups. Further study is required to determine whether this affected the results. It has been reported that thalidomide has a dose-dependent effect on OS in MM, 43 but the minimal effective dosage of thalidomide is still unknown. The thalidomide dosage (200 mg/day) in the present study is the minimum used in other reports, 33 but many patients could not tolerate a higher dose. This may be due to the relatively low body mass index of Chinese patients compared with those in the West. 44 The OS rate and CR rate associated with TBD in the present study were both better for the patients given the TBD regimen than those on T-VAD, however they did not show statistical significance. This may be because of the small number of cases investigated. Bortezomib-dexamethasone has previously been shown to give a markedly improved CR rate compared with VAD (14.8% versus 6.4%). 15 The OS rate was not reported in that study.
The TBD and T-VAD regimens were generally well tolerated in the present study, with no patient discontinuing treatment because of toxic effects. The most common toxic effect of treatment in the current study was peripheral neuropathy, the development of which is enhanced by both thalidomide and bortezomib. 45 Peripheral neuropathy is considered the most clinically important adverse effect of bortezomib, occurring in 6% of MM patients when used with thalidomide and dexamethasone treatment; 31, 42 however, toxicity is reversible in the majority of patients. 46 Common side-effects of thalidomide therapy include rash, sedation, neuropathy, DVT and teratogenicity. 30 Most side-effects of thalidomide are mild or moderate when used as a monotherapy, 28 however, a high risk of DVT has been reported among MM patients who received thalidomide combined with dexamethasone or doxorubicin. 21 Thalidomide is usually administered via continuous i.v. infusion, requiring a central line and increasing the risk of catheter-related infections and thrombosis. 47 In spite of anticoagulant prophylaxis, DVT occurred in 16.7% of the TBD group and 27.3% of the T-VAD group. The most frequent toxic effects of a haematological nature in the present study were neutropaenia and thrombocytopaenia. There were no significant differences in overall toxicity between the TBD and T-VAD regimens.
In conclusion, the addition of thalidomide to bortezomib-dexamethasone or VAD regimens was effective in the treatment of the newly diagnosed MM patients studied. The CR rate was higher with the TBD regimen than with the T-VAD regimen and there was no difference in OS; neither of these showed a statistically significant difference. Further studies are required to determine the role of thalidomide in these two regimens.
